Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer. - Wikidata - wikimedia - TriplyDB

Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.

Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.

http://www.wikidata.org/entity/Q38707608

about

Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers: Companion diagnostics for personalized medicine.Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs).Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics.Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy.Glutamate-cysteine ligase catalytic subunit is associated with cisplatin resistance in lung adenocarcinoma.Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs).A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX A distinct class of antioxidant response elements is consistently activated in tumors with NRF2 mutations A combination of curcumin and oligomeric proanthocyanidins offer superior anti-tumorigenic properties in colorectal cancer The Influence of Metabolism on Drug Response in Cancer

P2860

Q41817959-DAE1DDFC-90AB-4495-8289-D6ACE11B879B Q41911837-D1B26EF6-725D-45B7-8185-783BB40D517D Q41912547-1C784BAD-10EB-4671-96B4-6F74660E0078 Q47289203-7533A004-4525-407D-9615-BBDF0EB73C10 Q50145747-006AAFA5-C6D0-4728-ABCB-F3D27546DC2D Q51768229-EB3D7E40-7A0B-4B0C-B80C-0EA79F2B6730 Q57148983-3EBF099C-95F3-423F-9993-1085D0AEF947 Q58718413-5E293C59-5681-4F94-B951-10506C8CC4C0 Q58740657-1536E6F4-162E-4BB2-B7EA-A1D9A72CB2FE Q59136910-7349BBBD-EB4E-4619-A8C2-B3E5B36EF711

P2860

Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.

http://www.wikidata.org/entity/Q38707608

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Mitochondrial "power" drives t ...... utic targets in breast cancer.

@en

type

label

Mitochondrial "power" drives t ...... utic targets in breast cancer.

@en

prefLabel

Mitochondrial "power" drives t ...... utic targets in breast cancer.

@en

P1433

Q38707608-1D759B5C-BCC8-4473-99F2-17857BBFC074

P1476

Q38707608-5606EE45-D8A8-46EE-8421-114328815C74

P2093

Q38707608-0A158E1A-7FB1-4719-BD7C-57732E004315

Q38707608-8AD19158-71D8-42DE-96D0-5F285D28D6CD

Q38707608-C4588EF5-5462-42CE-81E0-9DD87953D6DD

P2860

Q38707608-25CFDD28-E4BE-4253-BF63-6D28EC1A6CF1

Q38707608-26122191-BDF0-4E9F-8CBE-E5C331991090

Q38707608-341568EF-2E4F-423B-8DE4-343670F7C433

Q38707608-53E80852-AB0E-4F03-B656-7EA45C8153B0

Q38707608-549B3749-2B2A-4094-8C82-4EF758334FAC

Q38707608-5F5DE5D1-C64B-4B9F-894E-89F54BF20810

Q38707608-68F36AFC-A37B-4D4C-9A65-BD0DC44D7F00

Q38707608-6DFBC438-B925-4C13-B862-3B10F9405658

Q38707608-7C7141BE-8D86-4FE6-ABFC-366A0C51F525

Q38707608-8120DF65-2690-4071-ADE6-4B57804A8D7B

P304

Q38707608-5CD12E26-43CD-4252-AF81-14B9BE836E61

P31

Q38707608-B06B7EC4-C804-4715-8120-479E167640DF

P356

Q38707608-57ACD1D2-7C26-4935-AD2B-F2D974BDDD85

P407

Q38707608-D279CED4-74D0-42AC-82F2-F57BD38ADF98

P433

Q38707608-3AFECF3B-0182-4D2D-A95C-DBBD502C12CA

P478

Q38707608-80689E95-41D0-4202-A82E-C91B3570FB32

P50

Q38707608-33822CBE-505B-4694-AA05-F1EAFC416017

Q38707608-53DB4896-5A86-4EB4-B97E-E283C27F0877

P577

Q38707608-D8AB95F4-0B67-4432-BAA3-71B9F2D286C5

P698

Q38707608-3D095A6B-5C84-4F28-8A71-F1E95D1EB0C4

P932

Q38707608-5053FAB2-5F2E-4B8E-9DD4-01B425C48FA8

P356

ONCOTARGET.15852

P1433

P1476

Mitochondrial "power" drives t ...... utic targets in breast cancer.

@en

P2093

Anna Rita Cappello

http://www.w3.org/2001/XMLSchema#string

Diego Sisci

http://www.w3.org/2001/XMLSchema#string

Marco Fiorillo

http://www.w3.org/2001/XMLSchema#string

P2860

Application of metabolomics in drug resistant breast cancer research

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase

Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.

Oral N-acetylcysteine rescues lethality of hepatocyte-specific Gclc-knockout mice, providing a model for hepatic cirrhosis.

Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure.

Endocrine-responsive breast cancer and strategies for combating resistance.

Selective estrogen receptor modulation: concept and consequences in cancer.

P304

20309-20327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.15852

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Michael P. Lisanti

Federica Sotgia

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28411284

http://www.w3.org/2001/XMLSchema#string

P932

5386764

http://www.w3.org/2001/XMLSchema#string